Review

Bone Marrow Transplantation (2005) 35, 107–119. doi:10.1038/sj.bmt.1704715 Published online 25 October 2004

How and when should we monitor chimerism after allogeneic stem cell transplantation?

P Bader1, D Niethammer1, A Willasch1, H Kreyenberg1 and T Klingebiel2

  1. 1University Children's Hospital, Tübingen, Germany
  2. 2University Children's Hospital, Frankfurt, Germany

Correspondence: Dr P Bader, University Children's Hospital, Department of Pediatric Hematology and Oncology, Hoppe-Seyler-Stras zlige 1, D-72070 Tübingen, Germany. E-mail: peter.bader@med.uni-tuebingen.de

Top

Abstract

Summary:

Chimerism analysis has become an important tool for the peri-transplant surveillance of engraftment. It offers the possibility to realize impending graft rejection and can serve as an indicator for the recurrence of the underlying malignant or nonmalignant disease. Most recently, these investigations have become the basis for treatment intervention, for example, to avoid graft rejection, to maintain engraftment and to treat imminent relapse by pre-emptive immunotherapy. This invited review focuses on the clinical implications of characterization of hematopoietic chimerism in stem cell transplantation.

Keywords:

chimerism, allogeneic stem cell transplantation

Extra navigation

.

naturejobs

ADVERTISEMENT